An Ex Vivo Model of HIV-1 Latency and Reactivation using Primary Memory Cells
使用原代记忆细胞的 HIV-1 潜伏期和再激活的离体模型
基本信息
- 批准号:8212276
- 负责人:
- 金额:$ 37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-02-15 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:AgonistAntigensAreaBiological ProcessBiologyCD4 Positive T LymphocytesCellsEffector CellElementsEventExperimental ModelsFutureGene ExpressionGenesGoalsHIVHIV-1HumanIndividualInfectionInflammationInflammatoryKnowledgeLatent VirusLifeMemoryModelingMolecularPhysiologicalProcessProvirusesRegulationRelative (related person)Signal PathwaySignal TransductionStimulusStudy modelsSystemT memory cellT-Lymphocyte SubsetsTrans-ActivatorsVesicular stomatitis Indiana virusViralViral GenesVirusVirus Latencycell typecytokinein vivolatent infectionnovelpermissivenesspublic health relevancereactivation from latencytranscription factortranslational study
项目摘要
DESCRIPTION (provided by applicant): The proposed studies use a novel experimental model of viral latency and reactivation that utilizes primary memory cells as targets. Using this system, we plan to understand in detail the mechanisms that HIV-1 uses to establish latency in vivo, as well as the physiological signals that trigger viral reactivation. Knowledge from these areas will be applicable in future translational studies that will seek compounds mimicking or antagonizing the relevant signaling pathways, with the ultimate goal of destroying the latent reservoir.
PUBLIC HEALTH RELEVANCE: HIV-1 in infected individuals establishes a relatively small, but long-lived reservoir of latently infected cells. Latent infection is associated with low or no viral gene expression and, accordingly, appears to be non-cytopathic. Latent viruses can undergo reactivation, giving rise to new productive infections that carry full pathogenic potential. The cell type that harbors this long-lived, latent viral reservoir is thought to consist of quiescent memory T cells. We present a novel ex-vivo model for the study HIV latency as well as its reactivation. This model faithfully recapitulates salient features of the in vivo latent reservoir. For example, latent proviruses in this system are devoid of any detectable gene expression, yet, they are perfectly competent for gene expression when reactivated by a number of external stimuli. This model uses primary, human CD4+ lymphocytes and viral integration is polyclonal. This powerful, yet straighforward experimental system will allow us to (i) assess the relative permissivenes of various CD4+ T cell subsets to harbor latent proviruses; (ii) explore signaling pathways that may preclude the establishment of latent infections and/or induce reactivation of latent proviruses; and (iii) explore the use of select agonists and antagonists of the relevant signaling pathways to experimentally manipulate latency and reactivation. Ultimately, HIV-1 eradication will require a profound understanding of the biological processes that control entry and exit from latency.
描述(由申请方提供):拟定研究使用了一种新的病毒潜伏期和再激活实验模型,该模型利用原代记忆细胞作为靶点。使用这个系统,我们计划详细了解HIV-1用于建立体内潜伏期的机制,以及触发病毒再激活的生理信号。来自这些领域的知识将适用于未来的转化研究,这些研究将寻求模仿或拮抗相关信号通路的化合物,最终目标是破坏潜在的水库。
公共卫生相关性:HIV-1在感染者体内建立了一个相对较小但寿命较长的潜伏感染细胞库。潜伏性感染与低或无病毒基因表达相关,因此似乎是非细胞病变性的。潜伏的病毒可以重新激活,引起新的具有完全致病潜力的生产性感染。这种长期潜伏的病毒库的细胞类型被认为是由静止的记忆T细胞组成的。我们提出了一种新的离体模型的研究艾滋病毒的潜伏期,以及它的再激活。该模型忠实地概括了体内潜伏库的显著特征。例如,该系统中的潜伏前病毒缺乏任何可检测的基因表达,然而,当被许多外部刺激重新激活时,它们完全有能力进行基因表达。该模型使用原代人CD 4+淋巴细胞,病毒整合是多克隆的。这个强大而直接的实验系统将使我们能够(i)评估各种CD 4 + T细胞亚群对潜伏性前病毒的相对允许性;(ii)探索可能阻止潜伏性感染建立和/或诱导潜伏性前病毒再活化的信号通路;和(iii)探索使用相关信号传导途径的选择激动剂和拮抗剂来实验性地操纵潜伏期和再激活。 最终,根除HIV-1需要对控制进入和退出潜伏期的生物过程有深刻的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VICENTE PLANELLES其他文献
VICENTE PLANELLES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VICENTE PLANELLES', 18)}}的其他基金
Control of HIV-1 Transcription by CPSF6 and PP2A
CPSF6 和 PP2A 对 HIV-1 转录的控制
- 批准号:
10693519 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
CRISPR/Cas9 technology toward understanding HIV latency in primary cells
CRISPR/Cas9 技术有助于了解原代细胞中的 HIV 潜伏期
- 批准号:
9203550 - 财政年份:2016
- 资助金额:
$ 37万 - 项目类别:
CRISPR/Cas9 technology toward understanding HIV latency in primary cells
CRISPR/Cas9 技术有助于了解原代细胞中的 HIV 潜伏期
- 批准号:
9303273 - 财政年份:2016
- 资助金额:
$ 37万 - 项目类别:
Preclinical Development of Ingenol and HDACi Toward HIV Eradication
巨大戟二萜醇和 HDACi 根除 HIV 的临床前开发
- 批准号:
9049020 - 财政年份:2015
- 资助金额:
$ 37万 - 项目类别:
The Effects of ART on Platelets and HIV-Associated Thrombosis
ART 对血小板和 HIV 相关血栓形成的影响
- 批准号:
8847014 - 财政年份:2014
- 资助金额:
$ 37万 - 项目类别:
Activity of novel drug candidates in primary cell models of HIV latency
HIV潜伏原代细胞模型中新候选药物的活性
- 批准号:
8326800 - 财政年份:2011
- 资助金额:
$ 37万 - 项目类别:
An Ex Vivo Model of HIV-1 Latency and Reactivation using Primary Memory Cells
使用原代记忆细胞的 HIV-1 潜伏期和再激活的离体模型
- 批准号:
8613428 - 财政年份:2010
- 资助金额:
$ 37万 - 项目类别:
An Ex Vivo Model of HIV-1 Latency and Reactivation using Primary Memory Cells
使用原代记忆细胞的 HIV-1 潜伏期和再激活的离体模型
- 批准号:
8418764 - 财政年份:2010
- 资助金额:
$ 37万 - 项目类别:
An Ex Vivo Model of HIV-1 Latency and Reactivation using Primary Memory Cells
使用原代记忆细胞的 HIV-1 潜伏期和再激活的离体模型
- 批准号:
8019124 - 财政年份:2010
- 资助金额:
$ 37万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 37万 - 项目类别:
Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:














{{item.name}}会员




